ESP Block vs Control for Pain Control Following Percutaneous Nephrolithotomy

Conditions

• Nephrolithotomy, Percutaneous

Eligibility Criteria

Sex

ALL

Age

18 Years - N/A

Healthy Volunteers

Not accepted

Interventions

• Erector Spinae Plane Block — PROCEDURE
  The Anesthesiologist will use ultrasound-guided technique and inject 30mL of 0.5% ropivacaine with 4 mg of dexamethasone or saline placebo control into the erector spinae muscle, superficial to the tips of the thoracic transverse processes
• Ropivacaine 0.5% Injectable Solution — DRUG
  The Anesthesiologist will use ultrasound-guided technique and inject 30mL of 0.5% ropivacaine with 4 mg of dexamethasone or saline placebo control into the erector spinae muscle, superficial to the tips of the thoracic transverse processes
• Dexamethasone — DRUG
  The Anesthesiologist will use ultrasound-guided technique and inject 30mL of 0.5% ropivacaine with 4 mg of dexamethasone or saline placebo control into the erector spinae muscle, superficial to the tips of the thoracic transverse processes

Study Details

The purpose of this study is to investigate the use of the erector spinae (ESP) block in reducing the morphine milligram equivalent (MME) consumption post percutaneous nephrolithotomy. Objectives: 1. \- Determine if there is a significant effect on post percutaneous nephrolithotomy MME consumption with the usage of an ESP block vs. saline control. 2. \- Determine if there is a significant effect on reported pain levels with the use of an ESP block vs. saline control in post percutaneous nephrolithotomies.

Key Dates

Start date

Aug 9, 2021

Status verified

Apr 2026

Primary completion

Dec 31, 2027

Completion

Jun 30, 2028

Study Design

Enrollment

128 participants (estimated)

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

OTHER

Arms

• Active Comparator: ESP Group
  One 30mL syringe containing 30mL of 0.5% ropivacaine and 4 mg of dexamethosone-
• Sham Comparator: Sham Group
  One 30mL syringe containing 30mL of preservative free normal saline

Primary Outcome Measure

Opioid consumption (MME) [ Time Frame: First 24 hours postoperative ]

Central Contacts

• Jason Buehler, MD
  865-305-9220
  [email protected]
• Aimee Pehrson
  865-305-5432
  [email protected]

Locations (1)

Find similar trials in Knoxville, TN